IL265172B - A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof - Google Patents

A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof

Info

Publication number
IL265172B
IL265172B IL265172A IL26517219A IL265172B IL 265172 B IL265172 B IL 265172B IL 265172 A IL265172 A IL 265172A IL 26517219 A IL26517219 A IL 26517219A IL 265172 B IL265172 B IL 265172B
Authority
IL
Israel
Prior art keywords
layer
ezetimibe
pharmaceutically acceptable
rosuvastatin
group
Prior art date
Application number
IL265172A
Other languages
English (en)
Hebrew (he)
Other versions
IL265172A (en
Inventor
Alena Prokopova
Jaroslava Svobodova
Ondrej Dammer
Petr Mikes
Original Assignee
Sanofi Sa
Alena Prokopova
Jaroslava Svobodova
Ondrej Dammer
Petr Mikes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Alena Prokopova, Jaroslava Svobodova, Ondrej Dammer, Petr Mikes filed Critical Sanofi Sa
Publication of IL265172A publication Critical patent/IL265172A/en
Publication of IL265172B publication Critical patent/IL265172B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL265172A 2016-09-05 2017-08-31 A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof IL265172B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2016-539A CZ2016539A3 (cs) 2016-09-05 2016-09-05 Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
PCT/CZ2017/050037 WO2018041282A1 (en) 2016-09-05 2017-08-31 A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof

Publications (2)

Publication Number Publication Date
IL265172A IL265172A (en) 2019-05-30
IL265172B true IL265172B (en) 2022-09-01

Family

ID=59955311

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265172A IL265172B (en) 2016-09-05 2017-08-31 A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof

Country Status (13)

Country Link
US (1) US11786526B2 (enExample)
EP (1) EP3506888A1 (enExample)
JP (1) JP7094944B2 (enExample)
KR (1) KR102517765B1 (enExample)
CN (1) CN110418637A (enExample)
CZ (1) CZ2016539A3 (enExample)
EA (1) EA201990652A1 (enExample)
IL (1) IL265172B (enExample)
MA (1) MA46100A (enExample)
MX (1) MX389761B (enExample)
TW (1) TWI811195B (enExample)
WO (1) WO2018041282A1 (enExample)
ZA (1) ZA201901342B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
WO2022023206A1 (en) * 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin
CN120000605A (zh) * 2025-04-21 2025-05-16 山东齐都药业有限公司 瑞舒伐他汀依折麦布制剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064307A1 (en) * 2010-11-11 2012-05-18 Bilgic Mahmut Pharmaceutical compositions comprising rosuvastatin
WO2013166117A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
WO2015199356A1 (en) * 2014-06-25 2015-12-30 Hanmi Pharm. Co., Ltd. Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
CN103585157B (zh) * 2013-11-13 2016-02-03 武汉武药科技有限公司 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法
WO2016102400A1 (fr) * 2014-12-22 2016-06-30 L'oreal Composition comprenant un composé 4-(hétérocycloalkyl)-benzene-1,3-diol et un solvant particulier

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60319983T2 (de) * 2003-09-01 2009-07-23 Jpm - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
HUE038048T2 (hu) * 2009-07-28 2018-09-28 Egyt Gyogyszervegyeszeti Gyar Új granulálási eljárás és ezzel elõállított granulátum
WO2013066279A1 (en) 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
MX2012014970A (es) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN105310993A (zh) 2015-11-17 2016-02-10 深圳信立泰药业股份有限公司 一种含有依折麦布的药物组合物及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064307A1 (en) * 2010-11-11 2012-05-18 Bilgic Mahmut Pharmaceutical compositions comprising rosuvastatin
WO2013166117A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
US20140287042A1 (en) * 2012-05-01 2014-09-25 Althera Life Sciences Llc Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases
CN103585157B (zh) * 2013-11-13 2016-02-03 武汉武药科技有限公司 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法
WO2015199356A1 (en) * 2014-06-25 2015-12-30 Hanmi Pharm. Co., Ltd. Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
WO2016102400A1 (fr) * 2014-12-22 2016-06-30 L'oreal Composition comprenant un composé 4-(hétérocycloalkyl)-benzene-1,3-diol et un solvant particulier

Also Published As

Publication number Publication date
MA46100A (fr) 2019-07-10
TW201818938A (zh) 2018-06-01
MX2019002516A (es) 2019-06-17
TWI811195B (zh) 2023-08-11
JP2019526591A (ja) 2019-09-19
ZA201901342B (en) 2020-10-28
US20200009136A1 (en) 2020-01-09
CZ2016539A3 (cs) 2018-03-14
IL265172A (en) 2019-05-30
WO2018041282A1 (en) 2018-03-08
MX389761B (es) 2025-03-20
JP7094944B2 (ja) 2022-07-04
EA201990652A1 (ru) 2019-08-30
US11786526B2 (en) 2023-10-17
EP3506888A1 (en) 2019-07-10
CN110418637A (zh) 2019-11-05
KR20190045286A (ko) 2019-05-02
KR102517765B1 (ko) 2023-04-03
BR112019004269A2 (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
RU2206324C1 (ru) Фармацевтические композиции, содержащие ингибитор hmg редуктазы
US11786526B2 (en) Pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof
US20110027362A1 (en) Tablet having improved elution properties
US9399064B2 (en) Pitavastatin-containing preparation and method for producing same
US20140010876A1 (en) Pharmaceutical administration forms comprising 5-chloro-n-(methyl)-2-thiophenecarboxamide
EP4424373B1 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2006066961A1 (en) Solid pharmaceutical composition comprising valsartan
WO2018041281A1 (en) A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof
EP3236952B1 (en) Pharmaceutical tablet composition
CA3085455C (en) A solid oral dosage form comprising linagliptin
WO2011018185A2 (en) Pharmaceutical tablet comprising rosuvastatin calcium
JP5235676B2 (ja) （ｅ）−７−〔４−（４−フルオロフェニル）−６−イソプロピル−２−〔メチル（メチルスルホニル）アミノ〕ピリミジン−５−イル〕−（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸を含む医薬組成物
EP2934494B1 (en) Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
EA040745B1 (ru) Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения
RU2479310C2 (ru) Фармацевтическая композиция для лечения артериальной гипертензии и застойной сердечной недостаточности и способ ее получения
HK40114875A (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
BR112019004269B1 (pt) Comprimido oral compreendendo rosuvastatina e ezetimiba e seu método de preparação
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
WO2009016577A2 (en) A pharmaceutical composition comprising atorvastatin and niacin
WO2008068727A2 (en) Pharmaceutical composition comprising candesartan cilexetil
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤